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ABSTRACT 
Background    Preoperative transcatheter arterial 
chemoembolization (TACE) is administered to improve 
long-term outcome after surgical resection of hepatocel-
lular carcinoma (HCC). However, the survival benefit 
of preoperative TACE is controversial. We conducted a 
retrospective case-control study to evaluate the effect of 
preoperative TACE on prognosis. 
Methods    A total of 121 patients who underwent cu-
rative resection of HCC were divided into two groups 
according to whether they received preoperative TACE. 
We determined the control group (n = 34) and TACE 
group (n = 34) through propensity score matching. The 
primary endpoint of this study was overall survival, and 
the secondary endpoints were recurrence-free survival. 
Results    The overall survival rate and the recurrence 
free survival rate were significantly lower in the TACE 
group than in the control group (P = 0.014 and P = 0.043, 
respectively). Furthermore, recurrence free survival 
within less than 2 years after resection was significantly 
worse in the TACE group than in the control group (P = 
0.035). 
Conclusion    Preoperative TACE seemed to worsen 
the long-term outcomes of the patients who underwent 
surgical resection for the treatment of resectable HCC. 
Therefore, preoperative TACE should not be considered 
as a standard therapy in patients with resectable HCC.
Key words    surgical resection; survival; hepatectomy; 
neoadjuvant
Hepatocellular carcinoma (HCC) is the third leading 
cause of cancer death worldwide.1 Hepatic resection is 
considered a curative treatment for HCC, and the current 
the Japan Society of Hepatology, European Association 
for Study of the Liver and the American Association for 
the Study of Liver Diseases guidelines recommend re-
section as one of the first-line treatments for early stage 
HCC.2, 3 However, survival of HCC patients after hepat-
ic resection remains unsatisfactory. Tumor recurrence 
in the liver remnant complicates 70% of cases at 5 years 
after resection, reflecting either intrahepatic metastasis 
from the primary tumor or the development of de novo 
tumors.3–8 As a result, the 5-year overall survival rate 
after curative resection is reported to be 40%–50%.9 To 
counter this, several therapies have been administered 
prior to surgical resection, in an attempt to improve 
overall survival.10–12 Because the efficacy of preopera-
tive therapy before curative resection remains unclear, 
there is no preoperative therapy that is currently recom-
mended. 
 Transcatheter arterial chemoembolization (TACE) 
has been used since the beginning of the 1980s as a neo-
adjuvant therapy to improve long-term survival by pre-
venting cancer cell dissemination and intrahepatic recur-
rence.13–15 Several reports, including four randomized 
controlled trials, failed to demonstrate an improvement 
in survival rate with the administration of preoperative 
TACE.13, 16–18 Other studies, however, presented con-
flicting results.19–21 Key reasons for the continuing de-
bate are the considerable variation in background factors 
and radiological techniques involving HCC in previous 
studies and the various improvements in the TACE tech-
nique over the period of study. Because TACE has been 
shown to offer a survival advantage for patients with 
unresectable HCC,22, 23 in theory, preoperative TACE 
is considered to have positive effects on postoperative 
clinical course. Thus, the aim of the present study was 
to evaluate the survival benefit of preoperative TACE in 
patients who underwent resection of HCC.
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MATERIALS AND METHODS
Patients
We used a propensity-based matching case-control de-
sign in this study. A series of 189 consecutive patients 
who underwent a curative hepatic resection of primary 
hepatic cancer at our hospital between January 2004 
and December 2012 were included in the current study. 
All patients were diagnosed based on contrast-enhanced 
computed tomography (CT) or Gd ethoxybenzyl dieth-
ylenetriamine pentaacetic acid-enhanced magnetic reso-
nance imaging (MRI). Intrahepatic cholangiocarcinoma 
and combined HCC-cholangiocarcinoma tumors were 
excluded based on histological findings in the resected 
specimens. Patients with extrahepatic lesions, preoper-
atively diagnosed as vascular invasion, positive surgical 
margins or macroscopic residuals were also excluded. 
Patients who had undergone liver transplantation or 
surgical resection combined with ablation therapy were 
also excluded. On the basis of this exclusion criteria, 
121 patients were eligible in this study. Then, patients 
were divided into two groups according to whether they 
underwent preoperative TACE or not (the TACE group 
and control group). Thirty-four patients who had highly 
vascularized HCCs so that were considered to have sen-
sitivity for preoperative TACE by hepatologists assigned 
to the TACE group were administered preoperative 
TACE for two reasons: to improve long-term outcome (29 
cases), to be completely cured (5 cases).
 Written informed consent was obtained from all pa-
tients prior to TACE and surgery. Medical records were 
reviewed retrospectively after approval by the Institu-
tional Review Board (IRB) of our institution in accor-
dance with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments (IRB 
approval number: 1606A029). 
Variables
Data including patient characteristics [age, sex, body 
mass index (BMI), past medical history, presence or 
absence of prior local treatment for HCC, cause of hep-
atitis, Child–Pugh score, serum creatinine, albumin, 
total bilirubin, aspartate transaminase (AST), alanine 
transaminase (ALT), cholinesterase, platelet count, pro-
thrombin time, rate of indocyanine green disappearance 
15 min after injection (ICG-R15)], tumor characteristics 
[number of tumors, maximum diameter of tumor, al-
pha-fetoprotein (AFP) level], intra-operative data (extent 
of resection, surgical procedure, duration of surgery, in-
traoperative hemorrhage volume, length of hospital stay 
after surgical resection, postoperative complications), tu-
mor pathological findings (histotype and stage of fibrosis 
of nontumor-bearing liver according to the new Inuyama 
classification of chronic hepatitis), tumor recurrence and 
patient survival were collected from our database. Tu-
mor recurrence was diagnosed based on the findings of 
either CT or MRI. 
 Propensity score matching was performed using R 
version 3.1.3 software; the grouping variable was pre-
operative TACE and the matching variables were age, 
presence or absence of prior treatment, cause of hepa-
titis, Child–Pugh score, comorbidity (cardio-vascular 
disease and diabetes mellitus), serum albumin, bilirubin, 
AFP level, platelet count, prothrombin time, ICG-R15, 
number of tumors, tumor size, and stage of fibrosis of 
nontumor-bearing liver. The stage of fibrosis was the 
only histological finding included in this list of variables 
because this stage was rarely affected by preoperative 
TACE,24 and played an important role in the develop-
ment of de novo tumors in the remnant liver.25 Because 
histological findings concerning the primary tumor in 
the TACE group were believed to be affected by preop-
erative TACE, histological findings were not included in 
the list of variables to be matched.
Statistical analysis
We used R version 3.1.3 software for comparative sta-
tistical analysis. All continuous values are presented as 
the mean ± standard deviation and the median with inter 
quartile range. Statistical analysis was conducted using 
the chi-square test for categorical variables and Welch’s 
two-sample t test for continuous variables, with the ex-
ception of categorical variables containing factors less 
than 5, which were analyzed using Fisher’s exact test. 
Overall survival and recurrence free survival rates were 
calculated according to the Kaplan–Meier method and 
compared using the Gehan-Breslow-Wilcoxon test. All 
P values < 0.05 were considered significant. The prima-
ry endpoint of this study was overall survival, and the 
secondary endpoints were recurrence-free survival and 
postoperative complications.
RESULTS
Patient characteristics
Table 1 shows the characteristics of the 121 eligible 
patients before matching. Propensity score matching 
was carried out using 16 selected patient characteristics, 
tumor-related factors and surgical factors. Thirty-four 
patients were selected as the control group and included 
for further analysis. Tables 2 and 3 detail the clinico-
pathological characteristics and perioperative clinical 
outcomes, respectively, of the patients included in the 
current study. There were no significant differences 
in patient characteristics and perioperative outcomes 
between the control and TACE groups. To determine 
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Table 1. Patient background before propensity score matching
Control group (87) TACE (34)
Mean, SD Median [IQR] Mean, SD Median [IQR] P
Age (y) 67, s = 10.8 69 [62–74] 71.0, s = 8.5 72.5 [66.8–77.0] 0.036 
Prior treatment (%) 17 (20)   8 (24) 0.812 
Gender (male; %) 73 (84) 30 (88) 0.777 
BMI (kg/m²) 22.9, s = 3.0 22.8 [21.1–24.5] 23.1, s = 2.8 24.2 [20.6–25.4] 0.737 
Cause of hepatitis (%) NBNC 15 (17)   4 (11) 0.098 
HBV 39 (45) 10 (29)
HCV 24 (28) 14 (41)
Alcohol   9 (10)   5 (15)
Other   1 (1)   3 (9)
Child-Pugh score (%) 5 70 (80) 26 (76) 0.538 
6 13 (15)   8 (24)
7   2 (2)   0 
8   2 (2)   0 
Comorbidity (%) Cardio-vascular 
disease   9 (10)   5 (15) 0.534 
Diabetes 27 (31) 11 (32) 1.000 
Creatinine (mg/dL) 17.6, s = 9.1   0.75 [0.66–0.88]   0.78, s = 0.13   0.8 [0.70–0.87] 0.321 
Albumin (g/dL)   3.9, s = 0.5   4 [3.6–4.3]   3.9, s = 0.42   3.9 [3.7–4.2] 0.504 
Bilirubin (mg/dL)   0.73, s = 0.27   0.7 [0.5–0.9]   0.68, s = 0.22   0.7 [0.5–0.8] 0.292 
AST (IU/L) 38.5, s = 21.9 31 [23.5–48] 37.8, s = 21.9 33 [26.8–39.0] 0.881 
ALT(IU/L) 41.2, s = 46.2 26 [19–46] 36.3, s = 24.7 30 [23.3–39.8] 0.451 
Cholinesterase (IU/L)    195.1, s = 74.3    196.5 [135.2–241.5]    205.6, s = 80.0    191.5 [152.8–249.5] 0.510 
AFP (ng/mL)  7645.4, s = 39707   9.8 [3.7–80.5]  1251.4, s = 4445.4 10.1 [4.3–110] 0.144 
Platelet (/10³μL)    167, s = 63.2    161 [119.5–200.5]    179.5, s = 80.7    172.5 [120.5–213] 0.420 
Prothrombin time (%) 86.3, s = 18.0 87.7 [78.1–96.6] 88.8, s = 9.8 90 [81–97.6] 0.340 
ICG-R15 (%) 13.5, s = 6.9 13 [9–16] 17.8, s = 13.9 15 [13–20] 0.101 
Extent of hepatic 
resection (%)
Non-anatomic 38 (44) 17 (50) 0.851 
Segmentectomy 14 (16)   4 (12)
Sectorectomy 20 (23)   7 (21)
Lobe hepat
-ectomy 14 (16)   8 (24)
Hemi-hepat
-ectomy 11 (13)   3 (9)
Number of tumor (%) 1 69 (79) 25 (74) 0.758 
2 14 (16)   8 (24)
3   2 (2)   1 (3)
≥ 4   2 (2)   0
Maximum diameter 
(mm) 48.7, s = 41.5 30.5 [22–57.3] 40.8, s = 30.0 30 [21.3–48.8] 0.333 
Histotype (%) Well   5 (6)   3 (9) 0.106 
Moderate 77 (89) 26 (76)
Poor   3 (3)   4 (12)
NA   2 (2)   1 (3)
Fibrosis stagee* (%) 0 19 (22)   1 (3) 0.047 
1 23 (26)   7 (21)
2 10 (11)   8 (24)
3   8 (9)   5 (15)
4 24 (28)   8 (24)
*New Inuyama classification of chronic hepatitis. AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; BMI, body mass index; ICG-R15, 15-minute retention rates of indocyanine green; IQR, interquartile range; NA, not available; 
NBNC, non-HBV non-HCV hepatitis; TACE, transcatheter arterial chemoembolization; y, year(s).
273
Negative effects of preoperative TACE
Table 2. Patient background after propensity score matching
Control group (34) TACE group (34)
Mean, SD Median [IQR] Mean, SD Median [IQR] P
Age (y) 71.8, s = 6.7 72.5 [68–75] 71.0, s = 8.5 72.5 [66.8–77.0] 0.647 
Prior treatment (%) 11 (32)   8 (24) 0.588 
Gender (male; %) 25 (74) 30 (88) 0.217 
BMI (kg/m²) 23.6, s = 2.4 23.8 [22.2–25.2] 23.1, s = 2.8 24.2 [20.6–25.4] 0.457 
Cause of hepatitis (%) NBNC   8 (24)   4 (11) 0.171 
HBV 15 (38) 10 (29)
HCV 10 (29) 14 (41)
Alcohol   1 (3)   5 (15)
Other   1 (3)   3 (9)
Child-Pugh score (%) 5 27 (79) 26 (76) 0.765 
6   6 (18)   8 (24)
8   1 (3)   0 
Comorbidity (%) Cardio-vascular 
disease   5 (15)   5 (15) 1.000 
Diabetes   9 (26) 11 (32) 0.796 
Creatinine (mg/dL)   0.80, s = 0.23   0.76 [0.68–0.92]   0.78, s = 0.13   0.8 [0.70–0.87] 0.626 
Albumin (g/dL)   3.9, s = 0.4   4.0 [3.7–4.2]   3.9, s = 0.42   3.9 [3.7–4.2] 0.815 
Bilirubin (mg/dL)   0.70, s = 0.28   0.60 [0.53–0.88]   0.68, s = 0.22   0.7 [0.5–0.8] 0.663 
AST (IU/L) 40.1, s = 25.2 32 [26–48.3] 37.8, s = 21.9 33 [26.8–39.0] 0.602 
ALT(IU/L) 34.4, s = 26.0 24 [20–40.1] 36.3, s = 24.7 30 [23.3–39.8] 0.753 
Cholinesterase (IU/L)    205.1, s = 68.5    203.5[146–250.5]    205.6, s = 80.0    191.5 [152.8–249.5] 0.979 
AFP (ng/mL)  3342, s = 19120   5.8 [2.9–21.5]  1251.4, s = 4445.4 10.1 [4.3–110] 0.540 
Platelet (/10³μL)    181.1, s = 51.8    180.5 [143–217.8]    179.5, s = 80.7    172.5 [120.5–213] 0.923 
Prothrombin time (%) 91.5, s = 14.6 91.4 [80.6–102] 88.8, s = 9.8 90 [81–97.6] 0.396 
ICG-R15 (%) 16.4, s = 6.6 14 [12–19.5] 17.8, s = 13.9 15 [13–20] 0.596 
Extent of hepatic 
resection (%)
Non-anatomic 15 (44) 17 (50) 0.724 
Segmentectomy   7 (21)   4 (12)
Sectorectomy   6 (18)   7 (21)
Lobe hepat
-ectomy   5 (15)   8 (24)
Hemi-hepat
-ectomy   5 (15)   3 (9)
Number of tumor (%) 1 26 (76) 25 (74) 0.803 
2   6 (18)   8 (24)
3   2 (6)   1 (3)
Maximum diameter 
(mm) 42.3, s = 35.7 27 [22–50] 40.8, s = 30.0 30 [21.3–48.8] 0.851 
Histotype (%) Well   1 (3)   3 (9) 0.138
Moderate 32 (94) 26 (76)
Poor   0   4 (12)
NA   1 (3)   1 (3)
Necrosis rate (%) ≥ 90% 12 (35)
89–50%   4 (12)
< 50% 18 (53)
Fibrosis stage* (%) 0   4 (12)   1 (3) 0.515 
1   8 (24)   7 (21)
2   5 (15)   8 (24)
3   3 (9)   5 (15)
4 11 (32)   8 (24)
*New Inuyama classification of chronic hepatitis. AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; BMI, body mass index; ICG-R15, 15-minute retention rates of indocyanine green; IQR, interquartile range; NA, not available; 
NBNC, non-HBV non-HCV hepatitis; TACE, transcatheter arterial chemoembolization; y, year(s).
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methodological homogeneity of preoperative TACE, 
survey period was divided into two terms. Details of 
preoperative TACE were shown separately depends on 
periods of study in table 4. We also confirmed no signif-
icant difference of surgical outcomes between first- and 
second- half period of this study.
Overall and recurrence free survival
Among the 68 patients evaluated by propensity score 
matching, tumor recurrence occurred in 37 (54.4%) and 
death from all causes occurred in 26 (38.2%). Figure 1 
shows the overall survival rates in the two groups. The 
1-, 3-, and 5-year overall survival rates were 97.0%, 
93.9%, and 80.5%, respectively, in the control group and 
87.5%, 62.3%, and 62.3%, respectively, in the TACE 
group; the difference was statistically significant (P = 
0.014). The 1-, 3-, and 5-year recurrence-free survival 
rates were 90.8%, 62.6%, and 49.4%, respectively, in the 
control group and 68.7%, 44.9%, and 44.9%, respective-
ly, in the TACE group (Fig. 2; P = 0.043). Furthermore, 
Table 3. Outcomes of clinical course
Control group (34) TACE group (34)
Mean, SD Median [IQR] Mean, SD Median [IQR] P
Time from diagnosis to 
surgical resection (d) 66.2, s = 7.3 61.2 [33.8–75.5] 83.9, s = 35.0 87.5 [62.5–94.5] 0.134 
Intraoperative hemor-
rhage volume (mL)    946.7, s = 1135.5    502.5 [197.5–976.2]    935.9, s = 1340.4    392.5 [258.8–995] 0.975 
Operative duration 
(min)    437, s = 134.8    435 [324–515]    391, s = 150.9    378 [316–457] 0.197 
Postoperative compli-
cation*
Any grade 16 13 0.624 
Grade ≥ 3   5   8 0.537 
Hospital stay (d) 24.2, s = 19.7 19.5 [16–22] 20.5, s = 11.3 18 [14.3–22.3] 0.350 
*According to Clavien-Dindo classification. d, day(s); IQR, interquartile range; TACE, transcatheter arterial chemoembolization.
Table 4. Detail of methodology for preoperative TACE
Prior term (17) Latter term (17) P
Selectivity of hepatic artery (%) Lobe   2 (12)   3 (18) 0.617
Segment   4 (24)   5 (29)
Subsegment or more 10 (59)   9 (53)
Other (1st-branch of right inferior phrenic artery)   1 (6)   0
Chemotherapeutic agent (%) Epirubicin   2 (12)   3 (18) 0.153
Epirubicin plus mitomycin C   5 (29) 10 (64)
Cisplatin   6 (35)   2 (6)
Miliplatin   0   1 (6)
NA   4   1 
Embolic agent (%) Gelatin sponge 12 (71) 14 (82) NA
NA   5   3 
NA, not available; TACE, transcatheter arterial chemoembolization.
recurrence free survival within less than 2 years was sig-
nificantly worse in the TACE group than in the control 
group (Fig. 3; P = 0.035). With regard to type of surgical 
procedures, there were no significant difference between 
anatomical or non-anatomical resection among each 
groups (Fig. 4).
DISCUSSION
Preoperative TACE has been used in the following ways: 
as neoadjuvant chemotherapy for resectable HCCs,13 
as a conversion therapy for unresectable HCC through 
down-staging,21 to prepare for portal venous emboliza-
tion to reduce the risk of rapid growth of HCC,26 and 
with curative intent prior to salvaging surgical resection. 
In the current study, we evaluated the efficacy of TACE 
as a neoadjuvant therapy by comparing the prognosis of 
patients who underwent preoperative TACE and those 
who did not. The overall 5-year survival rate and the 
recurrence-free survival rate were significantly lower in 
the TACE group than in the control group. These find-
ings clearly indicate that preoperative TACE negatively 
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Fig. 1. Overall survival rates of the TACE and control groups. 
TACE, transcatheter arterial chemoembolization.
Fig. 2. Recurrence-free survival rates of the TACE and control 
groups. TACE, transcatheter arterial chemoembolization.
Fig. 3. Recurrence-free survival rates within less than 2 years af-
ter resection. TACE, transcatheter arterial chemoembolization.
affects the prognosis of patients with potentially resect-
able HCC. Similar findings have been reported in previ-
ous studies.18, 20, 27–31
 Several disadvantages of preoperative TACE have 
been postulated. First, it is likely that treatment with 
TACE delays surgical resection and that preoperative 
TACE renders surgical resection more difficult and de-
lays the operation time, resulting in intraoperative tumor 
feeding through collateral vessels.20, 27 Another possibil-
ity is that TACE mainly affects well-differentiated cells, 
without completely killing poorly differentiated cells 
that are related to poor prognosis.28 In the present study, 
however, such factors were unlikely to have influenced 
the poor prognosis observed in the TACE group because 
we performed statistical matching to reduce heterogene-
ity in patient profiles.
 As previously mentioned, there are two types of 
intrahepatic recurrence after resection, namely metasta-
sis of the primary tumor and secondary de novo tumor 
formation. Recurrence rates also peak twice after resec-
tion—recurrence in the early phase (˂  2 years) is mainly 
the result of metastases, whereas recurrence in the late 
phase (≥ 2 years) is attributable to new lesions.2, 32 Several 
studies have demonstrated a higher recurrence rate and 
lower overall survival in patients who underwent pre-
operative TACE.18, 29–31 In the present study, recurrence 
free survival within less than 2 years was significantly 
worse in the TACE group than in the control group, 
indicating the possibility that intrahepatic metastasis 
occurred more frequently in the TACE group than in 
the control group. Therefore, it is possible that increased 
early recurrence is related to the poor overall survival 
observed in the TACE group in the current study. 
 Recent studies have revealed that preoperative 
TACE may enhance the expression of vascular endothe-
lial growth factor protein, which encourages angiogene-
sis and results in metastasis.33 TACE may also increase 
the expression of a hypoxia-inducible factor that is relat-
ed to hepatic damage, resulting in carcinogenesis.34–36 
These molecular alterations might also be responsible 
for the low overall survival and high early-phase recur-
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rence rate observed in the TACE group in the current 
study. 
 This study had several limitations. First, histo-
pathological analysis could not be conducted prior to 
the interventions; therefore, the two groups could not be 
matched for histopathological characteristics, which may 
have been a confounding factor. Second, the study was 
retrospective in design, meaning that there were missing 
values for several variables. Finally, the sample size may 
have limited the statistical robustness of the results to 
some extent. However, consistent results were obtained 
in previous studies that support our current findings. 
With regard to survival rates in previous reports, 5-year 
overall and recurrence-free survival rates in patients 
with preoperative TACE were similar to our results.29 
Moreover, Roayaie et al reported outcomes of treatments 
other than resection among patients who were candidate 
for resection.37 Comparing our result to their results, 
resection with preoperative TACE may be superior to ra-
diofrequency ablation or TACE but inferior to resection, 
so that our result seem plausible.
 In conclusion, our results indicated that preoperative 
TACE seems to adversely affect the long-term outcomes 
of patients who underwent surgical resection to treat re-
sectable HCC. Ischemic stimulation of resectable HCC 
induced by preoperative TACE might worsen the post-
operative clinical course, especially in the early phase. 
Therefore, preoperative TACE should not be considered 
as a standard therapy for patients with potentially resect-
able HCC.
The authors declare no conflict of interest.
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